Aripiprazole (Abilify™) overdose in a child

Journal of Toxicology - Clinical Toxicology

Volumn 43, Issue 3, 2005, Pages 193-195

  Seifert, Steven A ^a   Schwartz, Michael D ^b   Thomas, Jerry D ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic drugs; Overdose; Partial dopamine agonists; Quinolinone

Indexed keywords

ACTIVATED CARBON; ALPHA ADRENERGIC RECEPTOR; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BMS 337039; BMS 337044; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEHYDROARIPIPRAZOLE; DIPHENHYDRAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG METABOLITE; HALOPERIDOL; HISTAMINE RECEPTOR; OPC 14857; PLACEBO; PROLACTIN; RISPERIDONE; SEROTONIN 1A ANTAGONIST; SEROTONIN 2 AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANXIETY; APPETITE DISORDER; ARTICLE; ATAXIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CASE REPORT; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL FEATURE; CLINICAL PROTOCOL; DIZZINESS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENETIC POLYMORPHISM; HALLUCINATION; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; INSOMNIA; LETHARGY; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC EXAMINATION; OBSESSIVE COMPULSIVE DISORDER; PHYSICAL EXAMINATION; PRESCHOOL CHILD; QT PROLONGATION; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOM; TARDIVE DYSKINESIA; UNCONSCIOUSNESS; VOMITING; INTOXICATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME; ANAMNESIS; CARDIOVASCULAR EFFECT; CHILD; DISEASE COURSE; DRUG DETERMINATION; DRUG INTOXICATION; GENERAL CONDITION IMPROVEMENT; LABORATORY TEST; MEDICAL EXAMINATION; VITAL SIGN;

ATAXIA;

ANTIPSYCHOTIC AGENTS; CHILD, PRESCHOOL; FEMALE; HUMANS; OVERDOSE; PIPERAZINES; QUINOLONES; TREATMENT OUTCOME; UNCONSCIOUSNESS;

EID: 18744414504     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.1081/CLT-200053097     Document Type: Article

References (11)

1. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers in the treatment of schizophrenia. Curr Drug Target CNS Neurol Disord 2002; 1(2):141-147.
2. Ozdemir V, Fourie J, Ozdener F. Aripiprazole Otsuka Pharmaceutical Co. Curr Opin Invest Drugs 2002; 3(1):113-120.
3. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Res 2003; 61(2-3):123-136.
4. Shapiro DA, Renock S, Arlington E, Chiodo LA, Liu LX, Sibley DR, Roth BR, Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28:1400-1411.
5. Sajatovic M. Treatment for mood and anxiety disorders: quetiapine and aripiprazole. Curr Psychiat Rep 2003; 5:320-326.
6. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part II: illustrating their mechanism of action. Clin Neurosci Update 2001; 62(12):923-924.
7. Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new atypical antipsychotic: phase II clinical trial results. Eur Neuropsychopharmacol 2002; 5(suppl 1):S186.
8. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiat 2003; 48(11):771-772.
9. Grunder G, Carlsson A, Wong D. Mechanism of new antipsychotic medication. Arch Gen Psychiatry 2003; 60:974-977.
10. Lofton AL, Kein-Schwartz W. Atypical experience: a case series of pediatric aripiprazole exposures. J Toxicol Clin Toxicol 2004; 42(5):715-716.
11. Sugiyama A, Satoh Y, Hashimoto K. In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appl Pharmacol 2001; 173:120-128.